NCT05477719

Brief Summary

The sleep apnea-hypopnea syndrome is characterized by the occurrence, during sleep, of abnormally frequent episodes of interruption of ventilation (apnea), or significant reduction in ventilation (hypopnea). The main symptoms of sleep apnea-hypopnea syndrome are daytime sleepiness (caused by the fragmentation and breakdown of sleep) and nocturnal snoring; possibly accompanied by the following symptoms: non-restorative sleep, difficulty concentrating, nocturia, cognitive disorders, libido disorders. The consequences of sleep apnea-hypopnea syndrome are multiple for the patient both in the short term and in the long term. The short-term manifestations are as follows: daytime sleepiness, reduced alertness, difficulty driving (risk of road accidents), difficulty performing tasks (risk of accidents at work), memory and concentration problems , learning difficulties (especially in children), mood disorders. In the end, there is an alteration in the quality of life of the patient. Sleep apnea-hypopnea syndrome also has long-term consequences: a link between sleep apnea-hypopnea syndrome and cardiovascular morbidity and mortality has been explored by several cohort studies. Nasal ventilation by continuous positive airway pressure is considered the reference treatment for sleep apnea-hypopnea syndrome. The use of nasal ventilation by continuous positive airway pressure, compared to no treatment, is not associated with a reduced risk of cardiovascular outcomes or death in patients with sleep apnea according to a recent meta-analysis. Mandibular advancement devices are an alternative treatment for nasal ventilation by continuous positive airway pressure. The acceptability of its treatments, whether nasal ventilation by continuous positive airway pressure or mandibular advancement devices, is not very good and some patients do not start treatment or abandon it because of the constraints related to these treatments. There is therefore a need to find other treatments. The overnight rostral fluid displacement from the legs, related to prolonged sitting can generate edema in the neck, more precisely in the upper airways, and therefore obstructive respiratory dysfunctions responsible for sleep apnea-hypopnea syndrome. Correlations between nocturnal fluid shifts and the number of apneas/hypopneas have been demonstrated Previous studies has shown a reduction in the apnea-hypopnea index by the daytime preventive wearing of medical compression, which can reduce the extent of leg edema and the displacement of nocturnal fluids. The aim of the present study is to show that daytime wearing of medical compression developed specifically to optimize its effect in this indication for 28 days versus not wearing it reduces the number of apneas/hypopneas in patients with sleep apnea-hypopnea syndrome.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
25

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Sep 2022

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

July 26, 2022

Completed
2 days until next milestone

First Posted

Study publicly available on registry

July 28, 2022

Completed
1 month until next milestone

Study Start

First participant enrolled

September 6, 2022

Completed
1.5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 13, 2024

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

March 13, 2024

Completed
Last Updated

May 5, 2026

Status Verified

May 1, 2026

Enrollment Period

1.5 years

First QC Date

July 26, 2022

Last Update Submit

May 2, 2026

Conditions

Keywords

Obstructive sleep apneaFluidSedentary livingCompression stockings

Outcome Measures

Primary Outcomes (1)

  • Change in the number of apneas/hypopneas

    28 days

Secondary Outcomes (8)

  • Proportion of patients with a 50% reduction in the apnea-hypopnea index

    28 days

  • Proportion of patients with an apnea-hypopnea index < 30/hour

    28 days

  • Proportion of patients with an apnea-hypopnea index < 15/hour

    28 days

  • Proportion of patients with a 50% reduction in the apnea-hypopnea index and an apnea-hypopnea index < 15/hour

    28 days

  • Change in sleep habits and characteristics

    28 days

  • +3 more secondary outcomes

Study Arms (2)

Compression stockings - No Compression

EXPERIMENTAL

The patient will wear specific compression stockings in the first phase, and no compression in the second phase of the study

Device: Wearing of specific compression stockings

No Compression - Compression stockings

EXPERIMENTAL

The patient won't wear anything in the first phase, and specific compression stockings in the second phase of the study

Device: Wearing of specific compression stockings

Interventions

The patient will wear specific compression stockings prevent the accumulation of fluids during the day in the lower part of the body and thus limiting the nocturnal drainage effect from the lower part of the body to the upper part of the body

Compression stockings - No CompressionNo Compression - Compression stockings

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • patient with moderate to severe sleep apnea-hypopnea syndrome confirmed by polysomnography dating less than 3 months with an index of apneas/hypopneas ≥ 15 apneas-hypopneas/h
  • having been previously treated with nasal ventilation by continuous positive airway pressure and mandibular orthosis and having stopped treatment for at least 10 days, regardless of the duration of use of these two treatments
  • or never treated for their sleep apnea-hypopnea syndrome satisfying the following 3 criteria
  • having 1 or 2 of the following signs daytime sleepiness, severe and daily snoring, feelings of suffocation or suffocation during sleep, daytime fatigue, nocturia, morning headaches.
  • absence of serious cardiovascular or respiratory comorbidity
  • absence of severe daytime sleepiness and/or accidental risk that could lead to direct or indirect bodily harm
  • stable weight (5% variation of the weight at the time of the polysomnography done within 3 months)
  • patient without varicose veins, without trophic disorder that could suggest moderate to severe superficial or deep venous insufficiency (dermatitis, hypodermatitis, active or healed ulcer)
  • sedentary patient (patient seated more than 8 h/d

You may not qualify if:

  • daily wearing of medical compression
  • patient with a contraindication to wearing a compression garment
  • patient unable to apply compression (preliminary test)
  • taking diuretics or venotonics
  • obesity (body mass index \> 30 kg/m2)
  • patient with leg dermatosis
  • patient with leg or thigh muscle trauma less than three months old
  • patient with sciatica, cruralgia or acute low back pain
  • pregnant or post-pregnancy women less than 6 months old or of childbearing age without an effective method of contraception
  • heart, liver or kidney failure
  • lymphedema of the lower limbs
  • cancer not considered to be in remission
  • history of abdominal radiotherapy

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Service des Pathologies du Sommeil Bâtiment EOLE GH Pitié-Salpêtrière

Paris, 75013, France

Location

MeSH Terms

Conditions

Sleep Apnea SyndromesSleep Apnea, Obstructive

Condition Hierarchy (Ancestors)

ApneaRespiration DisordersRespiratory Tract DiseasesSleep Disorders, IntrinsicDyssomniasSleep Wake DisordersNervous System Diseases

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
PREVENTION
Intervention Model
CROSSOVER
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

July 26, 2022

First Posted

July 28, 2022

Study Start

September 6, 2022

Primary Completion

March 13, 2024

Study Completion

March 13, 2024

Last Updated

May 5, 2026

Record last verified: 2026-05

Data Sharing

IPD Sharing
Will not share

Locations